Novozymes’ First-Half Ebitda Rises 11% Despite Market Uncertainty

Novozymes, a biotech firm, says its Ebitda for the first half of the year increased 11% to DK1.6 billion ($306 million) on sales up 9% to DK5.3 billion. All expectations for full-year 2011 are maintained, the company says.   “l'm satisfied with the half-year results, and although we're seeing increasing general uncertainty concerning the global economic situation and increased volatility in our end markets, we’re able to maintain our sales and earnings growth guidance for the full year,” says Steen Riisgaard, president and CEO.   Sales...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers